CapitalBio Technology Co., Ltd. (abbreviated “CapitalBio”) is the industrialization platform of the CapitalBio Corporation and the Beijing National Engineering Research Center for Biochips. CapitalBio has always adhered to independent innovation and achievement transformation and has a complete industrial chain integrating R&D, production, sales, and thrid-party independent medical laboratory services; and responds to the national policy of “prevention first.” The health policy integrates modern medicine and traditional Chinese medicine to form a large health industry section that includes health products, health management, medical rehabilitation, and big data. CapitalBio, based on a comprehensive biotechnology platform, provides instruments and equipment, supporting reagents and consumables, scientific research service outsourcing, experimental overall solutions, and so on. A variety of products and services have been exported to more than 30 countries and regions in North America, Europe, Asia, and so on. The biochip-related products developed have twice won the National Technology Invention Award’s second prize.
CapitalBio has developed a series of molecular detection products for hereditary diseases, infectious diseases, tumors, individualized medicine, disease susceptibility gene detection, and other urgently needed clinical products, as well as product services and overall solutions for accurate diagnosis and health. CapitalBio, a leading enterprise in the field of life sciences in China, has always adhered to the concept of “committed to technological innovation and realizing health dreams,”creating a full life cycle, comprehensive health service system, and a new medical and health service model suitable for China’s national conditions. Diversified health products benefit people’s livelihoods and help to build a “Healthy China”.
CapitalBio Corporation was established
CapitalBio's electromagnetic biochip was named “one of the top ten scientific and technological advances in China in 2000”
Dr. Jing CHENG, founder of CapitalBio Technology, was the first English monograph on biochips to be published
CapitalBio Technology obtained the first international patent authorization for biochips
EcoScan™-100, China’s first microarray chip scanner based on CCD detection, was introduced.
LuxScan™ 10K, China’s first dedicated laser scanner for microarray chips, was exported to the United States.
"HLA gene chip typing detection service system” is included in the scope of application of the China Bone Marrow Bank’s HLA detection reagents.
ISO9001 and ISO13485 certifications have been obtained.
Nature Biotechnology published self-developed microarray chip papers, and listed CapitalBio Technology as a recommended supplier of global microarray chip products and services.
Affymetrix, the world’s largest gene chip company, formed a strategic partnership.
The self-developed biochip instrument platform won the National Technology Invention Award’s Second Prize
Obtained laboratory accreditation from China National Accreditation Service for Conformity Assessment (CNASL2451)
The State Food and Drug Administration approved the first biochip industry standard developed by CapitalBio Technology
Establishment of the China Hematopoietic Stem Cell Donor Database Sample Bank
CapitalBio Technology became the first Roche NimbleGen certificated service provider in China
The Genetic Screening Project for hearing impaired disabled people with hereditary deafness in Beijing was complete successfully
CapitalBio Technology’s project to screen for the genes that cause neonatal deafness all over the world was included in the 2012 Beijing Municipal People’s Practical Project.
CapitalBio MedLab was the National Health and Family Planning Commission’s first batch of individualized medical testing pilot units.
A new generation of high-throughput gene sequencers has been launched
The National Health and Family Planning Commission has approved CapitalBio MedLab as the first batch of clinical pilot units using high-throughput gene detection technology for tumor diagnosis and treatment projects.
Deafness Gene Mutation Detection Kit and LuxScan™ 10K Microarray Chip Scanner obtained Medical Device License in Taiwan.
CapitalBio Technology launched a joint detection product for microRNA and AFP for the early detection of liver cancer.
In clinical trials in the United States, a genetic testing chip for common hereditary deafness in Caucasians obtained phased results.
CapitalBio Technology’s NIPT reached 1.5 million people, preventing the birth of more than 10,000 mentally handicapped children.
CapitalBio Technology’s genetic screening of newborn hereditary deafness has screened over 3.3 million people, directly preventing over 80,000 children and maternal family members from deafness caused by incorrect medication.
The number of people screened in the diabetes management project of CapitalBio Technology Chongqing Liangjiang New District exceeded 100,000, and nearly 10,000 people were diagnosed with diabetes for the first time.
CapitalBio Technology has drafted, promulgated, and implemented a total of 21 national and industry standards.
LeiJingTang, CapitalBio Technology’s Chinese medicine branch, was established in Beijing.
The “Respiratory Pathogens Nucleic Acid Detection Kit (Isothermal Amplification on Disk Chip)” developed by CapitalBio Technology, which includes the COVID-19, was approved for emergency medical devices by the State Food and Drug Administration and received CE-IVD certification
The COVID-19 Mobile Lab developed by CapitalBio Technology, as the first mobile detection bus in China, was put into use.
The SARS-CoV-2 integrated microfluidic chip analysis system, with samples in and results out, was CE-IVD certified.
CapitalBio (Chengdu) Technology is positioned in the product manufacturing link of the group company’s industrial chain, with biochips independently developed by the group company, relying on the strong scientific and technological research and development strength and core technology of CapitalBio Corporation and CapitalBio Technology (parent company). Reagent consumables, instruments and equipment, and other medical devices, as well as biochemical products, comprise modern medical testing and imaging equipment and molecular diagnostic reagents, the core of which are biochips and next-generation sequencing. Large-scale production; based on market needs and sales links, adopt a centralized and diverse business model, organize product production and manufacture; establish industry competitive advantages, and provide products needed by the market for the sales value chain; the overall value of the company.